

March 14, 2017



# OncoSec Announces First Technology Access Program Agreement with Inhibrx

SAN DIEGO, March 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a Technology Access Program (TAP) agreement with Inhibrx, LP, a privately held biotherapeutic company.

Under the agreement, Inhibrx will use OncoSec's proprietary gene delivery technologies; the GENESIS™ research generator and proprietary applicators, for preclinical discovery of antibodies.

"We initially announced the availability of the TAP in November, and I am excited to have Inhibrx signed on as the first company to use our devices for their internal research programs," said Punit Dhillon, OncoSec's Chief Executive Officer. "We believe this program helps to facilitate discovery efforts for TAP partners while advancing OncoSec's proprietary technologies. By making our devices available for non-exclusive research use to both industry and academic collaborators, for a small licensing fee, we are building our internal data set around GENESIS™ while expending minimal internal resources."

"The ability of OncoSec's TRACE™ technology to optimize *in vivo* gene expression for animal immunization provides advantages over traditional antibody discovery approaches, especially for difficult to express and complex transmembrane proteins," said Mark Lappe, Inhibrx's Chief Executive Officer. "We look forward to continuing to work with OncoSec through our TAP agreement to explore the use of *in vivo* electroporation for gene delivery and antibody discovery."

## **About OncoSec Research Technologies and Technology Access Program:**

The OncoSec GENESIS™ research generator was developed specifically for gene electro-transfer. It features customizable electroporation parameters for construct-specific optimization of expression, and it is the only *in vivo* electroporation device enabled with TRACE™ Technology (Tissue-Based, Real-Time Adaptive Control Electroporation.) TRACE™ technology incorporates an electrochemical tissue-sensing control system to automatically adjust pulse width and treatment duration in real time during the electroporation procedure. This feature enables tissue- and therapeutic-specific delivery optimization, maximizing uptake of the therapeutic while reducing unnecessary cell ablation or damage. In research models, GENESIS™ with TRACE™ has yielded higher and more consistent *in vivo* protein expression versus fixed-parameter electroporation, even in heterogeneous tissues.

Potential advantages of using GENESIS™ with TRACE™ for the objectives of animal immunization include cost savings versus recombinant protein administration, a shortened pre-immunization timeline relative to recombinant protein production, and display of the immunizing antigen in its native conformation. The latter benefit may be particularly relevant for certain therapeutic indications, including immuno-oncology, in which many key targets

require functional agonism and/or structurally-complex therapeutic modalities such as multimeric forms. To date, OncoSec has generated multiple high-titer antibody libraries against immuno-therapeutic targets.

The OncoSec Technology Access Program makes OncoSec's electroporation technologies available to collaborators for preclinical research. Devices are available for intratumoral, intradermal, and intramuscular delivery. For more information, please contact [bd@oncosec.com](mailto:bd@oncosec.com).

#### **About OncoSec Medical Incorporated:**

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit [www.oncosec.com](http://www.oncosec.com).

#### **About Inhibrx, LP:**

Inhibrx is a clinical stage biologic immunotherapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions. Inhibrx's proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen to focus and conditionally modulate immune activities and mediate enhanced signaling. Therapeutic proteins include multispecific and multivalent molecules designed and crafted using our composite modular single domain antibody technology. For more information visit [www.inhibrx.com](http://www.inhibrx.com).

#### **OncoSec Medical Incorporated Forward Looking Statements**

To the extent statements contained in this press release are not descriptions of historical facts *regarding OncoSec Medical Incorporated, they may be considered forward looking statements, as described in the Private Securities Litigation Reform Act of 1995, reflecting management's current beliefs and expectations. Forward looking statements speak only as of the date they are made, and they are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "focus," "forecast," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward looking statements contained in this press release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop and commercialize our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) our and our partners' ability to develop,*

*manufacture and commercialize our product candidates and to improve the manufacturing process; (v) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (vi) the rate and degree of acceptance of our product candidates; (vii) our ability to attract and retain key scientific or management personnel; (viii) the anticipated timing of clinical data availability; (ix) the anticipated timing of commercial launch of ImmunoPulse® IL-12; (x) our ability to meet our milestones; (xi) our expectations regarding our ability to obtain and maintain intellectual property protection; (xii) the level of our corporate expenditures; (xiii) the assessment of our technology by potential corporate partners; and, (xiv) the impact of capital market conditions on our Company.*

*Undue reliance should not be placed on forward looking statements. Such statements are subject to factors, risks and uncertainties, such as those described in our periodic filings with the Securities and Exchange Commission, including without limitation our Quarterly Reports on Form 10-Q, our annual reports on Form 10-K and other filings. Various factors may cause actual results to differ materially from those expressed or implied by such forward looking statements. We undertake no obligation to publicly update any forward-looking statements. OncoSec's investigational drug and device products have not been approved or cleared by the FDA.*

CONTACT:

Investor Relations  
OncoSec Medical Incorporated  
855-662-6732  
[investors@oncosec.com](mailto:investors@oncosec.com)

Media Relations:  
Laura Radocaj  
DGI Comm  
212-825-3210  
[media@oncosec.com](mailto:media@oncosec.com)



ONCOSEC<sup>TM</sup>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/oncosec-announces-first-technology-access-program-agreement-with-inhibrx-300423104.html>

SOURCE OncoSec Medical Incorporated